These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35804446)

  • 1. In silico prediction of UGT-mediated metabolism in drug-like molecules via graph neural network.
    Huang M; Lou C; Wu Z; Li W; Lee PW; Tang Y; Liu G
    J Cheminform; 2022 Jul; 14(1):46. PubMed ID: 35804446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational Prediction of Site of Metabolism for UGT-Catalyzed Reactions.
    Cai Y; Yang H; Li W; Liu G; Lee PW; Tang Y
    J Chem Inf Model; 2019 Mar; 59(3):1085-1095. PubMed ID: 30586295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5'-Diphospho-glucuronosyltransferase Substrates.
    Reddy MB; Bolger MB; Fraczkiewicz G; Del Frari L; Luo L; Lukacova V; Mitra A; Macwan JS; Mullin JM; Parrott N; Heikkinen AT
    Pharmaceutics; 2021 Aug; 13(9):. PubMed ID: 34575401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PreMetabo: An in silico phase I and II drug metabolism prediction platform.
    Hwang S; Shin HK; Shin SE; Seo M; Jeon HN; Yim DE; Kim DH; No KT
    Drug Metab Pharmacokinet; 2020 Aug; 35(4):361-367. PubMed ID: 32616370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using graph neural networks for site-of-metabolism prediction and its applications to ranking promiscuous enzymatic products.
    Porokhin V; Liu LP; Hassoun S
    Bioinformatics; 2023 Mar; 39(3):. PubMed ID: 36790067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential genoprotective role for UDP-glucuronosyltransferases in chemical carcinogenesis: initiation of micronuclei by benzo(a)pyrene and benzo(e)pyrene in UDP-glucuronosyltransferase-deficient cultured rat skin fibroblasts.
    Vienneau DS; DeBoni U; Wells PG
    Cancer Res; 1995 Mar; 55(5):1045-51. PubMed ID: 7866987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and optimization of the cocktail assay for rapid assessment of the activity of UGT enzymes in human and rat liver microsomes.
    Chen A; Zhou X; Cheng Y; Tang S; Liu M; Wang X
    Toxicol Lett; 2018 Oct; 295():379-389. PubMed ID: 30036684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Machine learning and structure-based modeling for the prediction of UDP-glucuronosyltransferase inhibition.
    Dudas B; Bagdad Y; Picard M; Perahia D; Miteva MA
    iScience; 2022 Nov; 25(11):105290. PubMed ID: 36304105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure and Protein-Protein Interactions of Human UDP-Glucuronosyltransferases.
    Fujiwara R; Yokoi T; Nakajima M
    Front Pharmacol; 2016; 7():388. PubMed ID: 27822186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Silico Prediction of Metabolic Reaction Catalyzed by Human Aldehyde Oxidase.
    Huang M; Zhu K; Wang Y; Lou C; Sun H; Li W; Tang Y; Liu G
    Metabolites; 2023 Mar; 13(3):. PubMed ID: 36984889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-drug interaction potential of antitumor acridine agent C-1748: The substrate of UDP-glucuronosyltransferases 2B7, 2B17 and the inhibitor of 1A9 and 2B7.
    Mróz A; Ryska I; Sominko H; Bejrowska A; Mazerska Z
    Pharmacol Rep; 2018 Oct; 70(5):972-980. PubMed ID: 30107347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of cloned and expressed human liver UDP-glucuronosyltransferases for analysis of drug glucuronide formation and assessment of drug toxicity.
    Burchell B; Ebner T; Baird S; Bin Senafi S; Clarke D; Brierley C; Sutherland L
    Environ Health Perspect; 1994 Nov; 102 Suppl 9(Suppl 9):19-23. PubMed ID: 7698078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus-inhibited multiple isoforms of UDP-glucuronosyltransferases (UGTs).
    Du Z; Wang G; Cao YF; Hu CM; Yang K; Liu YZ; Zhang CZ; Zhang WH; Zhu ZT; Sun HZ; Sun XY; Hong M; Fang ZZ
    Xenobiotica; 2018 May; 48(5):452-458. PubMed ID: 28548030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of glucuronidation in drug resistance.
    Mazerska Z; Mróz A; Pawłowska M; Augustin E
    Pharmacol Ther; 2016 Mar; 159():35-55. PubMed ID: 26808161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity.
    Mutlib AE; Goosen TC; Bauman JN; Williams JA; Kulkarni S; Kostrubsky S
    Chem Res Toxicol; 2006 May; 19(5):701-9. PubMed ID: 16696573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simple model predicts UGT-mediated metabolism.
    Dang NL; Hughes TB; Krishnamurthy V; Swamidass SJ
    Bioinformatics; 2016 Oct; 32(20):3183-3189. PubMed ID: 27324196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving Chemical Reaction Prediction with Unlabeled Data.
    Xie Y; Zhang Y; Wong KC; Shi M; Peng C
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico insights: chemical and structural characteristics associated with uridine diphosphate-glucuronosyltransferase substrate selectivity.
    Smith PA; Sorich MJ; McKinnon RA; Miners JO
    Clin Exp Pharmacol Physiol; 2003 Nov; 30(11):836-40. PubMed ID: 14678246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucuronidation in humans. Pharmacogenetic and developmental aspects.
    de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
    Clin Pharmacokinet; 1999 Jun; 36(6):439-52. PubMed ID: 10427468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards integrated ADME prediction: past, present and future directions for modelling metabolism by UDP-glucuronosyltransferases.
    Smith PA; Sorich MJ; Low LS; McKinnon RA; Miners JO
    J Mol Graph Model; 2004 Jul; 22(6):507-17. PubMed ID: 15182810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.